A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)
HM-GCG-201
Phase 2 other active
Quick answer
A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE) for Congenital Hyperinsulinism (CHI) is a Phase 2 program (other) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharm Research Associates (UK) Limited
- Indication
- Congenital Hyperinsulinism (CHI)
- Phase
- Phase 2
- Modality
- other
- Status
- active